Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (2973)	11/24/1997 3:30:00 PM
From: Bhag Karamchandani	Respond to of 6136

AGPH: prospects Although not an investor, I have followed AGPH for a longtime. What attracted me to the company was their science - they are not dependent on the success of one or two drugs- which is typically the 'make or break' scenario for a large number of biotechs. For the despondent investors, I have the following to offer by way of consolation based on facts: 1. AGPH has a current PE ratio of approx. 30 ( Earning per share of approx. $1.25 - CY conservative estiamte) 2. AGPH has a current growth rate of approx. 37% - exceeding its PE ratio. If this trend continues for the next three years , assuming this is the minimum period before new APPROVED AIDS therapies emerge on the market, and pessimistically assuming no role beyond this period for Viracept and no new drugs from AGPH , still makes the stock undervalued based on fundamentals. And my assumptions, I believe, are unrealistically pessimistic. IMHO. I wish I had the money to buy AGPH at these levels. This is not to suggest that I have any knowledge where the price will be tomorrow. I guess I expect the AGPH approach to drug design to deliver more than one successful drug every three years. Time will tell.